MTOR and cancer: The resulting ROS1 fusion genes drive oncogenic signaling through activation of multiple pathways, including mitogen‐activated protein kinase (MAPK)/extracellular signal‐regulated kinase (ERK), phosphoinositide 3‐kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR), and Janus kinase (JAK)/signal transducer and activator of transcription (STAT), promoting cancer cell survival, proliferation, and growth.